WY-14643
PPARα agonist / Selective PPARα agonist (EC50=0.63, 32 and >100 µM for PPARα,γ and δ, respectively).1 Displays anti-inflammatory activity2 and reduces LPS-induced inflammation in alveolar epithelial cells3. Induces “browning” of white adipocytes in combined treatment with retinoic acid.4 Stimulates ADAM10-mediated proteolysis of amyloid precursor protein in a mouse model.5 Down regulates NFκB transcriptional activity. Review.6
Biochemicals & reagents
50892-23-4
Pirinixic acid
1) Forman et al. (1997), Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta; Proc. Natl. Acad. Sci. USA, 94 4312 2) Devchand et al. (1996), The PPARalpha-leukotriene B4 pathway to inflammation control; Nature, 384 39 3) Heckler et al. (2015), PPAR-a activation reduced LPS-induced inflammation in aveolar epithelial cells; Exp. Lung Res., 41 393 4) Wang et al. (2015), WY14643 combined with all-trans retinoic acid acts via p38 MAPK to induce “browning” of white adipocytes in mice; Genet. Mol. Res., 14 6978 5) Corbett et al. (2015), Activation of peroxisome proliferator-activated receptor alpha stimulates ADAM10-mediated proteolysis of APP; Proc. Natl. Acad. Sci. USA, 112 8445 6) Merk et al. (2015), Pirinixic acids: flexible fatty acid mimetics with various biological activities; Future Med. Chem., 7 1597
RT
TARGET: Transcription factor; Cytochrome/MDR -- PATHWAY: PPAR; Fatty acid metabolism; Transcription -- DISEASE AREA: Inflammation; CancerIschemia; Diabetes